A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose) in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis.

Trial Profile

A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose) in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2012

At a glance

  • Drugs Certoparin sodium (Primary)
  • Indications Thrombosis
  • Focus Therapeutic Use
  • Acronyms MEMBRANE
  • Most Recent Events

    • 27 Oct 2012 Planned number of patients changed from 100 to 110 as reported by European Clinical Trials Database record.
    • 09 Jul 2012 Actual patient number added as reported by ClinicalTrials.gov.
    • 26 May 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2010-019200-23).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top